ReviewPharmaceuticals (Basel, Switzerland)2021
Role of Citicoline in the Management of Traumatic Brain Injury.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Efficacy and Safety of Cerebroprotein Hydrolysate I Combined with Rehabilitation Training in the Treatment of Provisional Intellectual Developmental Disorder in Children.Neuropsychiatric disease and treatment · 2025Trial
- Citicoline on the Barthel Index: Severe and moderate brain injury.Indian journal of pharmacologyTrial
- The impact of citicoline on brain mitochondrial dysfunction induced in rats after head irradiation.Scientific reports · 2025Article
- Preclinical evidence for the anxiolytic- and antidepressant-like effects of citicoline and imipramine in the sciatic nerve-ligated mice.IBRO neuroscience reports · 2024Article
- Traumatic brain injury: Advances in coagulopathy (Review).Biomedical reports · 2024Review
- Mitigating Traumatic Brain Injury: A Narrative Review of Supplementation and Dietary Protocols.Nutrients · 2024Review
- Inflammatory response in traumatic brain and spinal cord injury: The role of XCL1-XCR1 axis and T cells.CNS neuroscience & therapeutics · 2024Review
- Ten good reasons to consider gastrointestinal function after acute brain injury.Journal of clinical monitoring and computing · 2024Review
- Pathophysiology-Based Management of Secondary Injuries and Insults in TBI.Biomedicines · 2024Review
- CDP-choline to promote remyelination in multiple sclerosis: the need for a clinical trial.Neural regeneration research · 2023Review
- Traumatic brain injury and immunological outcomes: the double-edged killer.Future science OA · 2023Review
- The Role of PBulletin of experimental biology and medicine · 2023Article
- Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2023Review
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- A novel pharmacological treatment concept for neuroprotection in severe traumatic brain injury-Two case reports.Clinical case reports · 2022Article
- Dynamics of Choline-Containing Phospholipids in Traumatic Brain Injury and Associated Comorbidities.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head injury is among the most devastating types of injury, specifically called Traumatic Brain Injury (TBI). There is a need to diminish the morbidity related with TBI and to improve the outcome of patients suffering TBI. Among the improvements in the treatment of TBI, neuroprotection is one of the upcoming improvements. Citicoline has been used in the management of brain ischemia related disorders, such as TBI. Citicoline has biochemical, pharmacological, and pharmacokinetic characteristics that make it a potentially useful neuroprotective drug for the management of TBI. A short review of these characteristics is included in this paper. Moreover, a narrative review of almost all the published or communicated studies performed with this drug in the management of patients with head injury is included. Based on the results obtained in these clinical studies, it is possible to conclude that citicoline is able to accelerate the recovery of consciousness and to improve the outcome of this kind of patient, with an excellent safety profile. Thus, citicoline could have a potential role in the management of TBI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.